Therapy News and Research

RSS

Acrux reports Phase III trial results evaluating AXIRON for testosterone deficiency

Australian company, Acrux, today announced positive results from a Phase III trial evaluating the safety and efficacy of AXIRON™ in 155 men with testosterone deficiency (hypogonadism), across 26 sites in six countries.

29 Sep 2009

Diabetics should monitor their blood sugar levels to improve metabolic status

Diabetes patients should always control their own blood sugar values if this leads to improvements in their treatment. This is the view advocated by Michael Nauck of the Bad Lauterberg Diabetes Center and his coauthors in the current issue of Deutsches Ärzteblatt International (Dtsch Arztebl Int 2009; 106[37]: 587-94), who discuss sensible approaches to blood glucose self-monitoring.

29 Sep 2009

Januvia in combination with metformin or taken alone lowers blood sugar

A post-hoc analysis, presented at the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD), of data pooled from studies of 104 weeks in duration showed ‘Januvia’ (sitagliptin), when taken alone or in combination with metformin, provided significant blood sugar lowering over two years.

29 Sep 2009

Women feeling more positive about their genitals find it easier to orgasm

An Indiana University study published in the September issue of the International Journal of Sexual Health found that women who feel more positively about women's genitals find it easier to orgasm and are more likely to engage in sexual health promoting behaviors, such as having regular gynecological exams or performing vulvar self-examinations.

29 Sep 2009

Continuous chest compressions during CPR improve survival rates during cardiac arrest

Maximizing the proportion of time spent performing chest compressions during cardiopulmonary resuscitation (CPR) substantially improves survival in patients who suffer cardiac arrest outside a hospital setting, according to a multicenter clinical study that included UT Southwestern Medical Center.

29 Sep 2009

Radiation treatment after prostate cancer surgery eradicates recurrent cancer

The largest single-institution study of its kind has found few complications in prostate cancer patients treated with radiotherapy after surgery to remove the prostate. Men in this study received radiotherapy after a prostate-specific antigen (PSA) test following surgery indicated their cancer had recurred.

29 Sep 2009

NovoCure initiates newly-diagnosed GBM clinical trial

NovoCure, Ltd., a privately held medical device company focused on developing the Novo-TTF device, a non-invasive portable medical device for the treatment of cancer, announced the completion of a new funding round today. Key investors in this round included Pfizer Inc, Johnson & Johnson Development Corporation and Index Ventures.

29 Sep 2009

Estrogen withdrawal may play a significant role in joint pain during breast cancer treatment

Aromatase inhibitors, the same drugs that have buoyed long-term survival rates among breast cancer patients, also carry side effects including joint pain so severe that many patients discontinue these lifesaving medicines. New University of Pennsylvania School of Medicine research, however, has uncovered patterns that may help clinicians identify and help women at risk of these symptoms sooner in order to increase their chances of sticking with their treatment regimen.

29 Sep 2009

Researchers recommend hormone therapy prior to mammogram screenings

Researchers from Boston University School of Medicine (BUSM) are recommending that menopausal women on hormone therapy (HT) continue their treatment prior to having their annual mammogram screenings. These recommendations appear as an editorial in the current on-line issue of Journal of the North American Menopause Society.

29 Sep 2009

Proton therapy center to treat pediatric and adult cancer patients

The development of a proton therapy center in the Pacific Northwest has taken a significant step forward with the signing of a letter of intent between the Seattle Cancer Care Alliance (SCCA) and ProCure Treatment Centers Inc. (ProCure). SCCA and ProCure announced the agreement today and are moving the project forward to bring this advanced form of radiation therapy to adult and pediatric cancer patients.

29 Sep 2009

Conditional IDE approval for Flexstent Femoropopliteal Self Expanding Stent System

Flexible Stenting Solutions Inc. (“FSS”), a leading developer of next generation peripheral arterial and biliary stents, announced today that it has received Conditional Investigational Device Exemption (IDE) approval for its FlexStent® Femoropopliteal Self Expanding Stent System.

29 Sep 2009

Heparin-induced skin lesions may indicate platelets deficit

Heparin, a commonly used anticoagulant, can cause skin lesions, reports a study http://www.cmaj.ca/press/cmaj081729.pdf in CMAJ (Canadian Medical Association Journal) www.cmaj.ca.

29 Sep 2009

Mercy Memorial implements CDW's disaster recovery solution to increase reliability of critical clinical applications

CDW Healthcare, part of the public sector subsidiary of CDW Corporation and a leading provider of technology products and services to healthcare organizations, today announced that Mercy Memorial Hospital of Monroe, Mich., launched an extensive server virtualization and disaster recovery solution acquired from CDW Healthcare.

28 Sep 2009

The CDH Proton Therapy Center announces arrival of a 220-ton cyclotron for treating cancer

A 220-ton cyclotron, the core of what will soon be Illinois’ most advanced radiation treatment center, has ended a 5,000-mile journey that began in Belgium, arriving at the construction site of the CDH Proton Therapy Center, a ProCure Center, located in suburban Warrenville. Capable of accelerating protons, the cyclotron is the core piece of equipment used in proton therapy, an alternative to X-ray radiation that spares healthy tissue and results in far fewer short- and long-term treatment side effects.

28 Sep 2009

European Commission grants conditional marketing authorization for Gilead's Cayston

Gilead Sciences, Inc. announced today that the European Commission has granted conditional marketing authorization for Cayston® 75 mg powder and solvent for nebuliser solution (aztreonam lysine) for the suppressive therapy of chronic pulmonary infections due to Pseudomonas aeruginosa (P. aeruginosa) in patients with cystic fibrosis (CF) aged 18 years and older.

28 Sep 2009

Austrian Institute of Technology adopts Arrayit's Microarray Platform for detecting dangerous pathogens

Arrayit Corporation, a proprietary life sciences and technology leader, disclosed that its Microarray Platform has been adopted by Austrian Institute of Technology.

28 Sep 2009

Diabetic hypoglycemia remains a critical concern in young patients

A recent Lancet article predicted a doubling of new cases of type 1 diabetes in European children aged under 5, and a 70% rise in cases in children under 15 years - an incidence rate exceeding all previous predictions. Studies in the USA and other countries also suggest similar trends.

28 Sep 2009

Programme trains 3,500 Bristish therapists in CBT

At the World Congress on Psychosomatic Medicine which opened today in Torino Lord Richard Layard, Professor at the London School of Economics, has provided data on the British experience concerned with Improved Access to Psychological Therapy (IAPT).

28 Sep 2009

Thommen Medical launches two implant conditioning systems

Thommen Medical, a leading Swiss company in the area of the oral implantology, will officially launch the latest products in the evolution of implant surface technology, APLIQUIQ and INICELL, at the 2009 AAOMS Meeting in Toronto, Canada.

28 Sep 2009

FDA grants accelerated approval for Allos Therapeutics’ FOLOTYN

Allos Therapeutics, Inc. (Nasdaq:ALTH) today announced that last night the U.S. Food and Drug Administration (FDA) granted accelerated approval for FOLOTYNTM (pralatrexate injection) for use as a single agent for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

28 Sep 2009

Therapy News and Research

Acrux reports Phase III trial results evaluating AXIRON for testosterone deficiency

Diabetics should monitor their blood sugar levels to improve metabolic status

Januvia in combination with metformin or taken alone lowers blood sugar

Women feeling more positive about their genitals find it easier to orgasm

Continuous chest compressions during CPR improve survival rates during cardiac arrest

Radiation treatment after prostate cancer surgery eradicates recurrent cancer

NovoCure initiates newly-diagnosed GBM clinical trial

Estrogen withdrawal may play a significant role in joint pain during breast cancer treatment

Researchers recommend hormone therapy prior to mammogram screenings

Proton therapy center to treat pediatric and adult cancer patients

Conditional IDE approval for Flexstent Femoropopliteal Self Expanding Stent System

Heparin-induced skin lesions may indicate platelets deficit

Mercy Memorial implements CDW's disaster recovery solution to increase reliability of critical clinical applications

The CDH Proton Therapy Center announces arrival of a 220-ton cyclotron for treating cancer

European Commission grants conditional marketing authorization for Gilead's Cayston

Austrian Institute of Technology adopts Arrayit's Microarray Platform for detecting dangerous pathogens

Diabetic hypoglycemia remains a critical concern in young patients

Programme trains 3,500 Bristish therapists in CBT

Thommen Medical launches two implant conditioning systems

FDA grants accelerated approval for Allos Therapeutics’ FOLOTYN

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News